Lymphoma, Leukemia & Myeloma Congress

Lymphoma, Leukemia & Myeloma Congress The premier forum for healthcare professionals who study and manage patients with lymphoma, myeloma

For the past sixteen years, L&M has been the premier forum on the latest advances in lymphoma and myeloma. Over forty internationally-recognized leaders in molecular biology, pathology, immunology, translational and clinical research have been involved to provide expertise and guidance on recent developments in the basic science, translational medicine and clinical trials. The Congress features an interdisciplinary approach, special lectures, debates and interactive techniques to explore the controversial, the upcoming, and the exciting in myeloma, Waldenstrom’s macroglobulinemia, chronic lymphatic leukemia, lymphoma and Hodgkin’s disease.

Acute lymphoblastic leukemia (ALL) remains one of the toughest challenges in hematology — but innovation is reshaping th...
08/27/2025

Acute lymphoblastic leukemia (ALL) remains one of the toughest challenges in hematology — but innovation is reshaping the future.

At LL&M Congress, leading experts will share the latest evidence on:
- Next-gen CAR-T therapies & strategies to overcome resistance
- Transplantation timing guided by MRD & immunotherapy
- Tailored therapeutic approaches for older patients

This is where hematology’s most pressing questions meet evidence-based solutions. Don’t miss your chance to sharpen your expertise.
Register today: https://hubs.ly/Q03FVm1H0

Join the Network That Moves Blood Cancer Care Forward—Together.At the LL&M Congress, it’s more than education, it’s a co...
08/27/2025

Join the Network That Moves Blood Cancer Care Forward—Together.

At the LL&M Congress, it’s more than education, it’s a community. For 25 years, hematologists and oncologists from around the world have come together not only to share data and strategies, but to build meaningful, lasting connections that elevate care and support one another’s work.

Whether you're reconnecting with peers or expanding your professional circle, this is where collaboration meets purpose—and where progress begins.

📍 October 14–17 | New York City
🔗 Register today and connect with your peers: https://hubs.ly/Q03sF1Vl0

This year, we celebrates 25 years of impact in hematology-oncology.For a quarter century, LL&M Congress has been at the ...
08/23/2025

This year, we celebrates 25 years of impact in hematology-oncology.

For a quarter century, LL&M Congress has been at the forefront of advancing hematology-oncology education and collaboration.

We’re proud to celebrate this milestone with the global community of clinicians and researchers who’ve made it possible.

Read our official press release: https://hubs.ly/Q03F6ZBK0

A career that shaped how we treat CLL. A session that looks ahead to what’s next. After nearly 70 years in medicine, Dr....
08/22/2025

A career that shaped how we treat CLL. A session that looks ahead to what’s next.

After nearly 70 years in medicine, Dr. Kanti Rai has stepped away from clinical practice.
But his influence is far from over.

Known globally for developing the Rai Staging System, Dr. Rai transformed how we understand and manage chronic lymphocytic leukemia.

At this year’s LL&M Congress, we’re proud to continue his legacy with the RAI Lecture—a focused look at one of the most serious complications in CLL: Richter transformation.

Presented by Matt Davids, MD, MSc, the session will explore the clinical, molecular, and genetic risk factors for Richter transformation—including TP53 disruption, complex karyotype, clonal evolution, and more. Dr. Davids will also highlight emerging biomarkers and novel treatment approaches—from targeted therapy to immunotherapy—that could improve early identification, risk stratification, and outcomes for patients.

What you’ll learn:
- A deeper understanding of the biological risk factors behind Richter transformation
- New targeted and immunotherapy-based strategies currently in clinical exploration

Let’s honor his legacy and shape what’s next—together.
https://hubs.ly/Q03F0Pjy0

You change lives—let us empower your practice.Every day, hematology and oncology professionals like you make critical de...
08/19/2025

You change lives—let us empower your practice.

Every day, hematology and oncology professionals like you make critical decisions that shape patient journeys. The LL&M Congress is here to support that mission with the most comprehensive, clinically relevant education in blood cancers.

Over the course of four immersive days, you’ll gain practical insights into AML, ALL, MDS, MPN, lymphomas, myeloma, and CLL—delivered by 75+ leading experts. From the latest data to guideline-driven care, every session is designed to enhance your knowledge and elevate your impact.

Join us in celebrating 25 years of excellence in hematologic malignancies—and walk away with tools to deliver even better care tomorrow.

📍 October 14–17 | New York City
🔗 Secure your spot now: https://hubs.ly/Q03sF1_N0

Over the past decade, the CLL landscape has radically transformed and few have been more central to that evolution than ...
08/16/2025

Over the past decade, the CLL landscape has radically transformed and few have been more central to that evolution than Dr. Richard Furman.

A trusted leader, respected researcher, and clinician with a passion for progress, Dr. Furman has helped guide the field through breakthroughs in targeted therapy, prognostication, and patient-centered care. But as he’ll be the first to tell you...

We’re not done yet.

As co-chair of this year’s CLL Day at LL&M Congress, Dr. Furman will lead two essential sessions that explore where we are and where we must go next:
- CLL: What Is Left to Learn?
- Update from iwCLL 2025

Whether you're focused on today’s treatment decisions or tomorrow’s breakthroughs, these sessions will challenge your thinking and sharpen your clinical approach. Join Dr. Furman and the LL&M Congress community in advancing the future of CLL care.

Learn more: https://hubs.ly/Q03CCYb10

For patients with MGUS or smoldering myeloma, the stakes are high—but the signs aren’t always clear. It’s a question tha...
08/14/2025

For patients with MGUS or smoldering myeloma, the stakes are high—but the signs aren’t always clear. It’s a question that keeps even the most experienced hematologists up at night:

Who needs to be monitored closely?
Who needs treatment now?

At LL&M Congress, Dr. Irene Ghobrial will share how she navigates this gray area by breaking down the latest risk models, biomarkers, and emerging research into real-world decisions you can make with confidence.

Walk away knowing:
- How to spot patients at highest risk for progression
- Which clinical trials are shaping modern surveillance
- When to step in—and when to wait

Because sometimes, the hardest choice is to do nothing at all.

Learn more here: https://hubs.ly/Q03CzM0Q0

Follicular lymphoma has long carried a reputation: incurable, slow-growing, and often managed with watchful waiting. But...
08/12/2025

Follicular lymphoma has long carried a reputation: incurable, slow-growing, and often managed with watchful waiting. But what if that reputation is outdated?

At the LL&M Congress this October, Dr. Jonathan Friedberg will make the case for rethinking everything we’ve assumed about this disease—starting with the very first treatment decision. In his session on initial management, he explores whether our evolving understanding of follicular lymphoma means we should now be talking about cure.

It’s a conversation that blends real-world experience, clinical evidence, and a willingness to challenge the status quo.

Attend the session.
Ask the hard questions.
Leave with a new lens.

Learn more here: https://hubs.ly/Q03CqcGn0

Better education leads to better outcomes—because every insight you gain can make a difference in someone’s life. ❤️At t...
08/12/2025

Better education leads to better outcomes—because every insight you gain can make a difference in someone’s life. ❤️

At the 25th Annual Lymphoma, Leukemia & Myeloma Congress, we’re not just delivering updates, we’re empowering hematology and oncology professionals with the latest clinical evidence, treatment strategies, and real-world perspectives to improve patient care at every stage.

Join us for four focused days of interactive learning across leukemias, lymphomas, myeloma, and CLL—led by the experts moving the field forward.

📍 October 14–17 | New York City
🔗 Register today: https://hubs.ly/Q03sDXH50

There was a time when acute promyelocytic leukemia (APL) was one of the deadliest leukemias. Marked by sudden onset, hig...
08/11/2025

There was a time when acute promyelocytic leukemia (APL) was one of the deadliest leukemias. Marked by sudden onset, high risk of early complications, and devastating outcomes.

But medicine doesn’t stand still.

Thanks to the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), APL has transformed from a hematologic emergency to one of the field’s greatest success stories.

Today, survival rates have skyrocketed.

Still, success depends on speed and precision. Rapid diagnosis, immediate treatment, and risk-adapted therapy are not just best practices—they're life-saving decisions made in real time.

At the 25th Anniversary of LL&M Congress, Dr. Justin Kaner is spotlighting the management of APL. It’s your chance to reshape how you respond to one of hematology’s most time-sensitive conditions.

If seconds count, this session matters.

Register now at our discounted rate: https://hubs.ly/Q03C9WrT0

From podium to practice—real insights from the leaders shaping the future of hematologic care.Join us at the 25th Annual...
08/05/2025

From podium to practice—real insights from the leaders shaping the future of hematologic care.

Join us at the 25th Annual Lymphoma, Leukemia & Myeloma Congress, where over 75 renowned experts will present the latest clinical evidence, engage in high-level debates, and offer practical strategies you can immediately apply in your practice.

Whether you're managing AML, CLL, lymphomas, or myeloma, LL&M delivers the data and discussions that move the field forward—and help you do the same for your patients.

📍 October 14–17 | New York City
Register now: https://hubs.ly/Q03sDY6S0

138 of you said, “I have something to say.”And you said it loud and clear with a record-breaking number of abstract subm...
08/03/2025

138 of you said, “I have something to say.”
And you said it loud and clear with a record-breaking number of abstract submissions for this year's LLM Congress.

That’s 138 voices. 138 ideas. 138 reasons this year’s event will be unlike any other.

From global insights to local impact, the conversation is growing.
It's not too late to join in.

Be part of something big.
Register today here: https://hubs.ly/Q03B2KX30

Address

811 W 7th Avenue
New York, NY

Website

Alerts

Be the first to know and let us send you an email when Lymphoma, Leukemia & Myeloma Congress posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Our Story

For the past twenty years, L&M has been the premier forum on the latest advances in lymphoma and myeloma. Over forty internationally-recognized leaders in molecular biology, pathology, immunology, translational and clinical research have been involved to provide expertise and guidance on recent developments in the basic science, translational medicine and clinical trials. The Congress features an interdisciplinary approach, special lectures, debates and interactive techniques to explore the controversial, the upcoming, and the exciting in myeloma, Waldenstrom’s macroglobulinemia, chronic lymphatic leukemia, lymphoma and Hodgkin’s disease.